ACT Share Price

Open 194.10 Change Price %
High 194.10 1 Day -3.10 -1.59
Low 189.30 1 Week 9.45 5.19
Close 191.70 1 Month 64.50 50.71
Volume 1403 1 Year 63.30 49.30
52 Week High 196.00
52 Week Low 111.00
ACT Important Levels
Resistance 2 196.15
Resistance 1 194.32
Pivot 191.70
Support 1 189.08
Support 2 187.25
ETR Germany Most Active Stocks
CBK 7.27 3.56%
CBK 7.27 3.56%
DBK 17.44 5.76%
DBK 17.44 5.76%
EOAN 6.46 0.31%
EOAN 6.46 0.31%
DTE 15.29 1.53%
DTE 15.29 1.53%
DTE 15.29 1.53%
DTE 15.29 1.53%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
VG8 6.30 21.15%
BCY2 10.91 16.93%
5M71 39.00 13.70%
CUR 1.09 13.54%
CUR 1.09 13.54%
CUR 1.09 13.54%
I7N 0.52 13.04%
BPG 0.33 10.00%
BPG 0.33 10.00%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
M6YA 0.84 -60.00%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
E8X 0.25 -32.43%
GRF 0.80 -9.09%
GRF 0.80 -9.09%
GRF 0.80 -9.09%
More..

Actelion Ltd (ETR: ACT)

ACT Technical Analysis 5
As on 7th Dec 2016 ACT Share Price closed @ 191.70 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 140.05 & Strong Buy for SHORT-TERM with Stoploss of 149.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACT Target for December
1st Target up-side 220.26
2nd Target up-side 246.91
3rd Target up-side 273.55
1st Target down-side 144.24
2nd Target down-side 117.59
3rd Target down-side 90.95
ACT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.actelion.com
ACT Address
ACT
Gewerberstrasse 16
Allschwil, 4123
Switzerland
Phone: 41 61 565 65 65
Fax: 41 61 565 65 00
ACT Latest News
Interactive Technical Analysis Chart Actelion Ltd ( ACT ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Actelion Ltd
ACT Business Profile
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.